Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021

Diabetes Care (2020) Vol. 44, Iss. Supplement_1, pp. S111-S124
Open Access | Times Cited: 890

Showing 1-25 of 890 citing articles:

Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018
Michael Fang, Dan Wang, Josef Coresh, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 23, pp. 2219-2228
Open Access | Times Cited: 492
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Mengwei Li, Xiaowei Chi, Ying Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 405
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al.
Circulation (2022) Vol. 145, Iss. 9
Open Access | Times Cited: 376
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 372
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 393-406
Closed Access | Times Cited: 317
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 216
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Jennifer M. Trujillo, Wesley Nuffer, Brooke A. Smith
Therapeutic Advances in Endocrinology and Metabolism (2021) Vol. 12
Open Access | Times Cited: 184
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, et al.
Diabetologia (2022) Vol. 65, Iss. 8, pp. 1251-1261
Open Access | Times Cited: 184
Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline
Mary T. Korytkowski, Ranganath Muniyappa, Kellie Antinori-Lent, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 8, pp. 2101-2128
Open Access | Times Cited: 175
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Jorge I. Fonseca‐Correa, Ricardo Correa‐Rotter
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 150
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
Ting-Yao Wang, Rui-Fang Wang, Zhi-Ying Bu, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 4, pp. 259-268
Open Access | Times Cited: 145
Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes
David M. Nathan, John M. Lachin, Ashok Balasubramanyam, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 12, pp. 1063-1074
Open Access | Times Cited: 145
Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication
Joakim Nordanstig, Christian‐Alexander Behrendt, Iris Baumgärtner, et al.
European Journal of Vascular and Endovascular Surgery (2023) Vol. 67, Iss. 1, pp. 9-96
Open Access | Times Cited: 130
Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis
Απόστολος Τσάπας, Thomas Karagiannis, Panagiota Kakotrichi, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 9, pp. 2116-2124
Closed Access | Times Cited: 127
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chandani Patel Chavez, Kenneth Cusi, Sushma Kadiyala
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 29-38
Open Access | Times Cited: 118
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 111
Glucose biosensors in clinical practice: principles, limits and perspectives of currently used devices
Salvatore A. Pullano, Marta Greco, Maria Giovanna Bianco, et al.
Theranostics (2021) Vol. 12, Iss. 2, pp. 493-511
Open Access | Times Cited: 109
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs
Dhruv Mahtta, David J. Ramsey, Michelle Lee, et al.
Diabetes Care (2022) Vol. 45, Iss. 2, pp. 372-380
Open Access | Times Cited: 88
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
Tracey Weiss, Lingfeng Yang, Richard D. Carr, et al.
BMJ Open Diabetes Research & Care (2022) Vol. 10, Iss. 1, pp. e002517-e002517
Open Access | Times Cited: 80
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction
Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 20, pp. 2058-2068
Open Access | Times Cited: 78
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
David M. Williams, Hannah Jones, Jeffrey W. Stephens
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 281-295
Open Access | Times Cited: 76
Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
Elpiniki Rentzeperi, Stavroula Pegiou, Theocharis Koufakis, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 3, pp. 454-454
Open Access | Times Cited: 71
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
Christophe De Block, Clifford J. Bailey, Carol Wysham, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 3-17
Open Access | Times Cited: 71
Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy
Carolyn E. Cesta, Ran S. Rotem, Brian T. Bateman, et al.
JAMA Internal Medicine (2023) Vol. 184, Iss. 2, pp. 144-144
Open Access | Times Cited: 44
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
Nikita Simms-Williams, Nir Treves, Hui Yin, et al.
BMJ (2024), pp. e078242-e078242
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top